cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.13350522.v1
title: Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses

description: Human platelet lysates (HPLs), rich in various growth factors and cell growth-promoting molecules, encompass a new range of blood products that are being used for regenerative medicine, cell therapies, and tissue engineering. Well-characterized dedicated preparations, tailor-made to best fit specific therapeutic applications, are needed for optimal clinical efficacy and safety. Here, five types of HPL were prepared from the same platelet concentrates and extensively characterized to determine and compare their proteins, growth factors, cytokines, biochemical profiles, thrombin-generating capacities, thrombin-associated proteolytic activities, phospholipid-associated procoagulant potential, contents of extracellular vesicles expressing phosphatidylserine and tissue factor, and antioxidative properties. Our results revealed that all five HPL preparations contained detectable supraphysiological levels, in the ca. 0.1 ~ 350-ng/ml range, of all growth factors assessed, except insulin-like growth factor-1 detected only in HPL containing plasma. There were significant differences observed among these HPLs in total protein content, fibrinogen, complement components C3 and C4, albumin, and immunoglobulin G, and, most importantly, in their functional coagulant and procoagulant activities and antioxidative capacities. Our data revealed that the biochemical and functional properties of HPL preparations greatly vary depending upon their mode of production, with potential impacts on the safety and efficacy for certain clinical indications. Modes of preparation of HPLs should be carefully designed, and the product properties carefully evaluated based on the intended therapeutic use to ensure optimal clinical outcomes.
DOI: 10.6084/m9.figshare.10055333
title: Platelet count and mean volume in acute stroke: a systematic review and meta-analysis

description: Changes of mean platelet volume (MPV) and platelet count (PC) could be a marker or a predictor of acute stroke (AS). We conducted a systematic review and meta-analysis of the published literature on the reporting of MPV and PC in AS. Studies were included in accordance with Patient Population or Problem, Intervention, Comparison, Outcomes, and Setting framework. The PRISMA strategy was used to report findings. Risk of bias was assessed with the Newcastle-Ottawa Scale. We included 34 eligible articles retrieved from the literature. PC was significantly lower in AS patients [standardized mean difference (SMD) = − 0.30, (95% CI: − 0.49 to − 0.11), N = 2492, <i>P</i> = .002] compared with controls (N = 3615). The MPV was significantly higher [SMD = 0.52 (95% CI: 0.28–0.76), N = 2739, <i>P</i> &lt; .001] compared with controls (N = 3810). Subgroup analyses showed significantly lower PC in both ischemic stroke (Difference SMD = −0.18, 95% CI: −0.35–0.01) and hemorrhagic stroke (−0.94, −1.62 to −0.25), but only samples by citrate anticoagulant showed significantly lower result for patients compared to controls (−0.36, −0.68 to −0.04). Ischemic stroke patients had higher MPV (0.57, 0.31–0.83), and samples by Ethylenediaminetetraacetic acid (EDTA) anticoagulant showed significantly higher result for patients compared to controls (0.86, 0.55–1.17). PC and MPV appeared to be significantly different between patients with AS and control populations. MPV was significantly higher in ischemic stroke and PC was significantly lower in both ischemic and hemorrhagic strokes. These characteristics might be related to AS and associated with it. It is advisable to pay attention to elapsed time between phlebotomy and hematology analysis, anticoagulant and hemocytometer types in AS. This meta-analysis is registered on the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD42017067864 (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=67864).
DOI: 10.6084/m9.figshare.10055333.v1
title: Platelet count and mean volume in acute stroke: a systematic review and meta-analysis

description: Changes of mean platelet volume (MPV) and platelet count (PC) could be a marker or a predictor of acute stroke (AS). We conducted a systematic review and meta-analysis of the published literature on the reporting of MPV and PC in AS. Studies were included in accordance with Patient Population or Problem, Intervention, Comparison, Outcomes, and Setting framework. The PRISMA strategy was used to report findings. Risk of bias was assessed with the Newcastle-Ottawa Scale. We included 34 eligible articles retrieved from the literature. PC was significantly lower in AS patients [standardized mean difference (SMD) = − 0.30, (95% CI: − 0.49 to − 0.11), N = 2492, <i>P</i> = .002] compared with controls (N = 3615). The MPV was significantly higher [SMD = 0.52 (95% CI: 0.28–0.76), N = 2739, <i>P</i> &lt; .001] compared with controls (N = 3810). Subgroup analyses showed significantly lower PC in both ischemic stroke (Difference SMD = −0.18, 95% CI: −0.35–0.01) and hemorrhagic stroke (−0.94, −1.62 to −0.25), but only samples by citrate anticoagulant showed significantly lower result for patients compared to controls (−0.36, −0.68 to −0.04). Ischemic stroke patients had higher MPV (0.57, 0.31–0.83), and samples by Ethylenediaminetetraacetic acid (EDTA) anticoagulant showed significantly higher result for patients compared to controls (0.86, 0.55–1.17). PC and MPV appeared to be significantly different between patients with AS and control populations. MPV was significantly higher in ischemic stroke and PC was significantly lower in both ischemic and hemorrhagic strokes. These characteristics might be related to AS and associated with it. It is advisable to pay attention to elapsed time between phlebotomy and hematology analysis, anticoagulant and hemocytometer types in AS. This meta-analysis is registered on the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD42017067864 (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=67864).
DOI: 10.6084/m9.figshare.9974924
title: Influence of antiretroviral therapy and cardiovascular disease on the immature platelet fraction in patients living with HIV

description: Cardiovascular disease is an important contributor to morbidity and mortality in people living with HIV . The immature platelet fraction (IPF) is increased in HIV-negative patients with cardiovascular disease and evidence suggests that an enlarged IPF is associated with adverse cardiovascular events. In this multi-center observational study, we aimed to investigate how the IPF in people living with HIV is influenced by antiretroviral therapy and cardiovascular disease. Subjects without cardiovascular disease that received antiretroviral therapy showed a smaller IPF accompanied by lower D-dimer and C-reactive protein (CRP) levels compared to therapy-naïve subjects (mean IPF: 2.9% vs. 3.9%, <i>p</i> = .016; median D-dimer: 252 µg/L vs. 623 µg/L, <i>p</i> p = .004). No significant differences for the IPF, D-dimer or CRP were found between subjects on antiretroviral therapy with documented cardiovascular disease and therapy-naïve subjects. In conclusion, we observed a reduction in the IPF among subjects on therapy only in the absence of cardiovascular disease. In contrast, subjects receiving therapy that had documented cardiovascular disease showed an IPF comparable to therapy-naïve subjects. Future studies are needed to investigate if an enlarged IPF may serve as a biomarker in predicting adverse cardiovascular events in people living with HIV.
DOI: 10.6084/m9.figshare.9974924.v1
title: Influence of antiretroviral therapy and cardiovascular disease on the immature platelet fraction in patients living with HIV

description: Cardiovascular disease is an important contributor to morbidity and mortality in people living with HIV . The immature platelet fraction (IPF) is increased in HIV-negative patients with cardiovascular disease and evidence suggests that an enlarged IPF is associated with adverse cardiovascular events. In this multi-center observational study, we aimed to investigate how the IPF in people living with HIV is influenced by antiretroviral therapy and cardiovascular disease. Subjects without cardiovascular disease that received antiretroviral therapy showed a smaller IPF accompanied by lower D-dimer and C-reactive protein (CRP) levels compared to therapy-naïve subjects (mean IPF: 2.9% vs. 3.9%, <i>p</i> = .016; median D-dimer: 252 µg/L vs. 623 µg/L, <i>p</i> p = .004). No significant differences for the IPF, D-dimer or CRP were found between subjects on antiretroviral therapy with documented cardiovascular disease and therapy-naïve subjects. In conclusion, we observed a reduction in the IPF among subjects on therapy only in the absence of cardiovascular disease. In contrast, subjects receiving therapy that had documented cardiovascular disease showed an IPF comparable to therapy-naïve subjects. Future studies are needed to investigate if an enlarged IPF may serve as a biomarker in predicting adverse cardiovascular events in people living with HIV.
DOI: 10.6084/m9.figshare.12851078
title: MicroRNA-126 is a regulator of platelet-supported thrombin generation

description: Circulating microRNA (miRNA) expression profiles correlate with platelet reactivity. MiR-126 is a promising candidates in this regard. We generated a transgenic zebrafish line with thrombocyte-specific overexpression of miR-126. Laser injury of the posterior cardinal vein of 5 day-old larvae was performed with or without antithrombotic pre-treatment. Platelet-like structures (PLS) derived from human megakaryocytes transfected with miR-126 were also evaluated for procoagulant activity. Finally, we studied the correlation between miR-126 level and thrombin generation markers in a cohort of stable cardiovascular patients. Control zebrafish developed small thrombocyte-rich thrombi at the site of vessel injury, without vessel occlusion. The miR-126 transgenic line developed an occluding thrombus in 75% (95% CI: 51–91%) of larvae. Pre-treatment with the direct thrombin inhibitor argatroban, but not aspirin, prevented vessel occlusion in the transgenic line (0% occlusion, 95%CI: 0–18%). Upon activation, human PLS showed an increased procoagulant profile after miR-126 transfection compared to control. Finally, the plasma levels of miR-126, but not a control platelet-derived miRNA, correlated with markers of <i>in vivo</i> thrombin generation in a cohort of 185 cardiovascular patients. Our results from three complementary approaches support a key role for miR-126 in platelet-supported thrombin generation and open new avenues in the tailoring of antithrombotic treatment.
DOI: 10.6084/m9.figshare.12851078.v2
title: MicroRNA-126 is a regulator of platelet-supported thrombin generation

description: Circulating microRNA (miRNA) expression profiles correlate with platelet reactivity. MiR-126 is a promising candidates in this regard. We generated a transgenic zebrafish line with thrombocyte-specific overexpression of miR-126. Laser injury of the posterior cardinal vein of 5 day-old larvae was performed with or without antithrombotic pre-treatment. Platelet-like structures (PLS) derived from human megakaryocytes transfected with miR-126 were also evaluated for procoagulant activity. Finally, we studied the correlation between miR-126 level and thrombin generation markers in a cohort of stable cardiovascular patients. Control zebrafish developed small thrombocyte-rich thrombi at the site of vessel injury, without vessel occlusion. The miR-126 transgenic line developed an occluding thrombus in 75% (95% CI: 51–91%) of larvae. Pre-treatment with the direct thrombin inhibitor argatroban, but not aspirin, prevented vessel occlusion in the transgenic line (0% occlusion, 95%CI: 0–18%). Upon activation, human PLS showed an increased procoagulant profile after miR-126 transfection compared to control. Finally, the plasma levels of miR-126, but not a control platelet-derived miRNA, correlated with markers of <i>in vivo</i> thrombin generation in a cohort of 185 cardiovascular patients. Our results from three complementary approaches support a key role for miR-126 in platelet-supported thrombin generation and open new avenues in the tailoring of antithrombotic treatment.
DOI: 10.6084/m9.figshare.12851078.v1
title: MicroRNA-126 is a regulator of platelet-supported thrombin generation

description: Circulating microRNA (miRNA) expression profiles correlate with platelet reactivity. MiR-126 is a promising candidates in this regard. We generated a transgenic zebrafish line with thrombocyte-specific overexpression of miR-126. Laser injury of the posterior cardinal vein of 5 day-old larvae was performed with or without antithrombotic pre-treatment. Platelet-like structures (PLS) derived from human megakaryocytes transfected with miR-126 were also evaluated for procoagulant activity. Finally, we studied the correlation between miR-126 level and thrombin generation markers in a cohort of stable cardiovascular patients. Control zebrafish developed small thrombocyte-rich thrombi at the site of vessel injury, without vessel occlusion. The miR-126 transgenic line developed an occluding thrombus in 75% (95% CI: 51–91%) of larvae. Pre-treatment with the direct thrombin inhibitor argatroban, but not aspirin, prevented vessel occlusion in the transgenic line (0% occlusion, 95%CI: 0–18%). Upon activation, human PLS showed an increased procoagulant profile after miR-126 transfection compared to control. Finally, the plasma levels of miR-126, but not a control platelet-derived miRNA, correlated with markers of <i>in vivo</i> thrombin generation in a cohort of 185 cardiovascular patients. Our results from three complementary approaches support a key role for miR-126 in platelet-supported thrombin generation and open new avenues in the tailoring of antithrombotic treatment.
DOI: 10.6084/m9.figshare.11369094.v1
title: Transcriptomic analysis of patients with immune thrombocytopenia treated with eltrombopag

description: In the last years, the use of thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, has improved the management of immune thrombocytopenia (ITP). Moreover, eltrombopag is also active in patients with aplastic anemia and myelodysplastic syndrome. However, their mechanisms of action and signaling pathways still remain controversial. In order to gain insight into the mechanisms underlying eltrombopag therapy, a gene expression profile (GEP) analysis in patients treated with this drug was carried out. Fourteen patients with chronic ITP were studied by means of microarrays before and during eltrombopag treatment. Median age was 78 years (range, 35–87 years); median baseline platelet count was 14 × 10<sup>9</sup>/L (range, 2–68 × 10<sup>9</sup>/L). Ten patients responded to the therapy, two cases relapsed after an initial response and the remaining two were refractory to the therapy. Eltrombopag induced relevant changes in the hematopoiesis, platelet activation and degranulation, as well as in megakaryocyte differentiation, with overexpression of some transcription factors and the genes <i>PPBP, ITGB3, ITGA2B, F13A1, F13A1, MYL9</i> and <i>ITGA2B</i>. In addition, <i>GP1BA, PF4, ITGA2B, MYL9, HIST1H4H</i> and <i>HIST1H2BH</i>, genes regulated by <i>RUNX1</i> were also significantly enriched after eltrombopag therapy. Furthermore, in non-responder patients, an overexpression of Bcl-X gene and genes involved in erythropoiesis, such as <i>SLC4A1</i> and <i>SLC25A39</i>, was also observed. To conclude, overexpression in genes involved in megakaryopoiesis, platelet adhesion, degranulation and aggregation was observed in patients treated with eltrombopag. Moreover, an important role regarding heme metabolism was also present in non-responder patients.
DOI: 10.5281/zenodo.4743776
title: Sexual performance and survival of sterile Ceratitis capitata VIENNA 8 (Diptera: Tephritidae) males inoculated with Beauveria bassiana

description: Data of the study Sexual performance and survival of sterile Ceratitis capitata VIENNA 8 (Diptera: Tephritidae) males inoculated with Beauveria bassiana
DOI: 10.5281/zenodo.4743775
title: Sexual performance and survival of sterile Ceratitis capitata VIENNA 8 (Diptera: Tephritidae) males inoculated with Beauveria bassiana

description: Data of the study Sexual performance and survival of sterile Ceratitis capitata VIENNA 8 (Diptera: Tephritidae) males inoculated with Beauveria bassiana
DOI: 10.5281/zenodo.4742924
title: Assemblies for NEC manuscript

description: Metagenomic assemblies for manuscript "Necrotizing enterocolitis is preceded by increased gut bacterial replication, Klebsiella, and fimbriae-encoding bacteria"
DOI: 10.5281/zenodo.4742923
title: Assemblies for NEC manuscript

description: Metagenomic assemblies for manuscript "Necrotizing enterocolitis is preceded by increased gut bacterial replication, Klebsiella, and fimbriae-encoding bacteria"
DOI: 10.34740/kaggle/dsv/2209932
title: YouTube Trending Video Dataset (updated daily)
DOI: 10.6084/m9.figshare.12851096
title: Development of an Intervention for Improving Ingestion in Elders with Oropharyngeal Dysphagia

description: To describe the development of a dysphagia management intervention for elders with sarcopenic oropharyngeal dysphagia (OD). The intervention development was guided by the UK Medical Research Council framework for developing and evaluating complex interventions. The steps included identification of the problem theory, the evidence base, the theory underpinning the intervention, the expected change mechanisms and a first draft of an intervention manual. This involved literature reviews and involvement of stakeholders, experts, and members of the target group. A manualized client-centered and activity-based intervention that integrates functional resistance training of skills essential for a safe and efficient swallowing during ingestion of daily meals was developed for elders with sarcopenic OD. The intervention is informed by occupational therapy theory, self-determination theory, motor learning and affordance theory, and international standards for OD diets. The development steps resulted in a multicomponent intervention ready for feasibility testing before examining intervention efficacy.
DOI: 10.6084/m9.figshare.12851096.v1
title: Development of an Intervention for Improving Ingestion in Elders with Oropharyngeal Dysphagia

description: To describe the development of a dysphagia management intervention for elders with sarcopenic oropharyngeal dysphagia (OD). The intervention development was guided by the UK Medical Research Council framework for developing and evaluating complex interventions. The steps included identification of the problem theory, the evidence base, the theory underpinning the intervention, the expected change mechanisms and a first draft of an intervention manual. This involved literature reviews and involvement of stakeholders, experts, and members of the target group. A manualized client-centered and activity-based intervention that integrates functional resistance training of skills essential for a safe and efficient swallowing during ingestion of daily meals was developed for elders with sarcopenic OD. The intervention is informed by occupational therapy theory, self-determination theory, motor learning and affordance theory, and international standards for OD diets. The development steps resulted in a multicomponent intervention ready for feasibility testing before examining intervention efficacy.
DOI: 10.6084/m9.figshare.13369753
title: Validation and initial results of surveys exploring perspectives on risks and solutions for diagnostic and medication errors in primary care in Sweden

description: To (1) validate and (2) display initial results of surveys to health care professionals and patients on the importance and mitigation of specified risks for diagnostic and medication errors. For validation, psychometric properties were analysed by assessment of construct validity and internal consistency by factor analysis. Non-parametric analyses were used concerning areas of risk, and top ranking of solutions were reported descriptively. Primary health care in Sweden. Health care professionals (HCPs); including physicians, nurses and practice managers, as well as patients who had experienced diagnostic or medication errors. Psychometric properties of the surveys. Median ratings for risks and top rankings of solutions for professionals and patients. There were 939 respondents to the HCP survey. Construct validity resulted in a model with four dimensions: Patient-provider level; Support systems for every day clinical work; Shared information and cooperation between different caregivers; Risks in the environment. Internal consistency was acceptable with Cronbach’s α values above 0.7. Confirmatory factor analysis generally showed an acceptable fit. Initial results from the professionals showed the importance of continuity of care, a nationwide on-line medical platform and cooperation in transfer of care. The patient survey could not be validated because of low response rate. The HCP survey showed some contradicting results regarding model fit and may be tentatively acceptable but validity needs further study. HCP survey answers indicated that relational continuity of care and a nationwide on-line medical platform are highly valued.Current awarenessHealth care professionals and patients are rather untapped sources of knowledge regarding patient safety in primary health careMain statementsValidation is performed on a new survey capturing rating of risks and solutions.The validation of the health care professional survey is tentatively acceptable.Survey answers indicate that health care professionals’ and patients’ perspectives are complementary. Health care professionals and patients are rather untapped sources of knowledge regarding patient safety in primary health care Validation is performed on a new survey capturing rating of risks and solutions. The validation of the health care professional survey is tentatively acceptable. Survey answers indicate that health care professionals’ and patients’ perspectives are complementary.